SCHEMBL20927367

SCHEMBL20927367

Oc1ccc(NC(=S)NC2CC2)c(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
MAPT P10636 3/20 0.65
MAPK1 P28482 2/20 0.65
NPSR1 Q6W5P4 2/20 0.65
NPC1 O15118 2/20 0.65
CYP1A2 P05177 1/20 0.65
CYP2C19 P33261 1/20 0.65
ALDH1A1 P00352 8/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
HTT P42858 4/20 0.54
LMNA P02545 2/20 0.52
POLB P06746 1/20 0.50
ALOX12 P18054 1/20 0.48
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29419622 0.81 HTT (0.71) MEN1KMT2AMAPTNPSR1NPC1
SCHEMBL1322743 0.81 HTT (0.71) MEN1KMT2AMAPTNPSR1NPC1
SCHEMBL19957270 0.80 ALDH1A1 (0.63) MEN1KMT2AMAPTMAPK1NPSR1
SCHEMBL4349380 0.77 MEN1 (0.59) MEN1KMT2AMAPTMAPK1NPSR1
SCHEMBL19957272 0.76 MAPT (0.55) MEN1KMT2AMAPTMAPK1NPSR1
SCHEMBL29264920 0.76 S1PR1 (0.48) MEN1KMT2AMAPTMAPK1NPSR1
SCHEMBL21750908 0.76 RAB9A (0.76) MEN1KMT2ANPC1CYP2C19ALDH1A1
SCHEMBL21750902 0.76 RAB9A (0.72) MEN1KMT2ANPC1SMN1; SMN2HTT
SCHEMBL21750960 0.75 RAB9A (0.74) MEN1KMT2AMAPTMAPK1NPSR1
SCHEMBL28895412 0.74 HTT (0.54) MAPK1NPC1ALDH1A1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 MEN1 1450/4885KMT2A 1030/4885MAPT 777/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 MEN1 1450/4885KMT2A 1030/4885MAPT 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.